Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema

Figures & data

Figure 1 Visual acuity (VA) of all patients.

Table 1 Demographic Data (Standard Deviation)

Demographic Data	All Patients	Group 1	Group 2
Patients	22	12	10
Eyes	24	12	12
Age	65.6 (10.6)	67 (14)	64 (4)
Gender F/M	8/14	5/7	3/7
DM type 1	22.7%	33.3%	8.3%
DM type 2	77.3%	66.7%	91.7%
Duration of DMO in months	26.1 (23.8)	23.0 (24.7)	29.0 (24.0)
Previous number of injections
Bevacizumab	4.4 (2.9)	3.8 (2.4)	5.1 (3.3)
Triamcinolone	0.5 (0.7)	0.3 (0.5)	0.6 (0.9)
Laser
Macular	54.0%	42.7%	66.7%
Peripheral	50.0%	33.3%	66.7%
Pseudophakic	54.0%	58.3%	41.7%
Vitrectomy done	20.8%	25.0%	16,7%

Abbreviations: DM, diabetes mellitus; DMO, diabetic macular oedema; F, female; M, male.

Figure 2 Visual acuity (VA) of the patients that managed with one dexamethasone implant.

Figure 3 Visual acuity (VA) of the patients that needed two or three dexamethasone implants. The second implant was injected at day 156 and third implant at day 337.

Figure 4 Central retinal thickness (CRT) of the patients that managed with one dexamethasone implant.

Figure 5 Central retinal thickness (CRT) of the patients that needed two or three dexamethasone implants.

Table 2 Accumulation of Hyper-Reflective Spots (HRS) (Standard Deviation)

Hyper-Reflective Spots (HRS)
	All patients	Group 1	Group 2	DM1	DM2
Baseline	67 (20)	74 (22)	58 (12)	62 (16)	69 (21)
Treated	59 (22)	69 (13)	45 (25)	55 (22)	60 (23)

Figure 6 Hyper-reflective spots (HRS) in the inner nuclear layer (INL) and in the outer plexiform layer (OPL) are seen more prominently in the OCT before the dexamethasone implant. Magnification of Group 1 (A and B) and Group 2 (C and D) OCT pictures.

Figure 7 The OCT before and after dexamethasone implant. Group 1 (parafoveal cysts) before (A) and after (B) the dexamethasone implant. Group 2 before (C) and after (D) the dexamethasone implant.

Figure 8 Intraocular pressure (IOP).